TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28829227

Group type: EXPERIMENTAL
Intervention: Acute bout of moderate‐intensity treadmill exercise for 10, 20, 30, 45, or 60 minutes followed by a recovery period of 5, 15, or 30 minutes.
Number of subjects: 352

Group type: COMPARATOR
Intervention: Acute exercise (vs. no exercise) for various durations and recovery periods.
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Different acute exercise durations and recovery periods.
Number of subjects: 352
Study: 25772974

Group type: EXPERIMENTAL
Intervention: Web-based intervention (PA website and monthly tailored emails)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Center-based intervention (12 sessions of group exercising)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mixed intervention (combination of web- and center-based)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 149
Study: 24018083

Group type: EXPERIMENTAL
Intervention: TASKit (Train Anywhere Skill Kit)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simulation laboratory training
Number of subjects: 20
Study: 22057975

Group type: EXPERIMENTAL
Intervention: HRSD(ANX)
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: IDS-C(ANX)
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: HRSD(ANX) and IDS-C(ANX)
Number of subjects: 3453
Study: 19481046

Group type: EXPERIMENTAL
Intervention: Education intervention group (n = 87)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (n = 59)
Number of subjects: 146
Study: 17230081

Group type: EXPERIMENTAL
Intervention: Cultured epithelial autograft
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dulbecco's Modified Eagle's Medium (Control)
Number of subjects: 8
Study: 15007374

Group type: EXPERIMENTAL
Intervention: Lidocaine instillation enhanced by electromotive drug administration (EMDA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional lidocaine instillation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Local anesthesia (lidocaine instillation)
Number of subjects: 28
Study: 11441406

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic aneurysm resection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 48
Study: 9893772

Group type: COMPARATOR
Intervention: Conventional intravenous antibiotic therapy with cefamandole 1 g i.v. every 6 h for 7 days
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Abbreviated intravenous therapy with cefamandole (1 g i.v. every 6 h for 2 days) followed by oral therapy with cefaclor (500 mg every 8 h for 5 days)
Number of subjects: 95
Study: 8031068

Group type: EXPERIMENTAL
Intervention: Antacids in didanosine tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single oral dose of 300 mg isoniazid
Number of subjects: 12
Study: 2544345

Group type: EXPERIMENTAL
Intervention: Naloxone 100 micrograms/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naloxone 250 micrograms/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naloxone 25 micrograms/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naloxone (all doses)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cold-pressor test
Number of subjects: 8
Study: 31129760

Group type: EXPERIMENTAL
Intervention: Experimental 1 (Exp 1; symptom monitoring + report)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Experimental 2 (Exp 2; symptom monitoring + report + ONS PEP–guided evidence‐based symptom management education)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control (symptom monitoring)
Number of subjects: 249
Study: 30621679

Group type: EXPERIMENTAL
Intervention: Cognitive forcing tool
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 29179134

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy combined with nimotuzumab
Number of subjects: 107

Group type: COMPARATOR
Intervention: Chemoradiotherapy alone (Control)
Number of subjects: 107
Study: 25894531

Group type: EXPERIMENTAL
Intervention: Inhalation of 400 μg of salbutamol
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 24515980

Group type: EXPERIMENTAL
Intervention: Obliteration of nasal cavity and bilateral sinuses with bone cement (experimental group)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Native sinus architecture (control group)
Number of subjects: 8
Study: 22950546

Group type: EXPERIMENTAL
Intervention: Moderate level of transference intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: No transference intervention
Number of subjects: 100
Study: 20332469

Group type: EXPERIMENTAL
Intervention: Intensive tutored pelvic training program (group A)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Pelvic floor exercises performed by patients on their own (group B)
Number of subjects: 332
Study: 17346304

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (150 mg/day), n = 34
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo, n = 26
Number of subjects: 60
Study: 16291103

Group type: EXPERIMENTAL
Intervention: Workers' Compensation (WC)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Personal Injury (non-WC)
Number of subjects: 531
Study: 12016602

Group type: EXPERIMENTAL
Intervention: 5.0 mg hyperbaric bupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 7.5 mg hyperbaric bupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10.0 mg hyperbaric bupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 12.5 mg hyperbaric bupivacaine
Number of subjects: 40
Study: 10440603

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg three times daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7757359

Group type: EXPERIMENTAL
Intervention: Formula fed babies on high lactose content
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Formula fed babies on low lactose content
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (children without lactose intolerance)
Number of subjects: 66
Study: 2186587

Group type: EXPERIMENTAL
Intervention: Single infusion of 8 g fosfomycin and 1 g metronidazole at induction of anaesthesia (Group 1)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Bacitracin 250 mg plus neomycin 250 mg (as four tablets on three occasions over two days), metronidazole 500 mg tablets three times a day for one day, and ampicillin 1 g intravenously at induction of anaesthesia (Group 2)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Overall infection rate among evaluable patients
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mortality related to infective complications
Number of subjects: 149
Study: 6243242

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cyclophosphamide, methotrexate, vincristine) and radiation therapy
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Prophylactic whole brain irradiation
Number of subjects: 258

Group type: COMPARATOR
Intervention: Cyclophosphamide and radiation therapy
Number of subjects: 258
Study: 30787647

Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 27402397

Group type: EXPERIMENTAL
Intervention: Factual retelling condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free retelling condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional retelling condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three retelling conditions
Number of subjects: 0
Study: 25826704

Group type: EXPERIMENTAL
Intervention: UP4FUN intervention (1-2 school lessons per week for 6 weeks)
Number of subjects: 3147

Group type: EXPERIMENTAL
Intervention: UP4FUN intervention
Number of subjects: 3147

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3147
Study: 24187863

Group type: EXPERIMENTAL
Intervention: Jianjining granules and Western Medicine (prednisone or pyridostigmine bromide)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Jianjining granules
Number of subjects: 60
Study: 21860296

Group type: EXPERIMENTAL
Intervention: Simulation training (hands-on vaginal delivery simulation)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Lecture only (traditional lecture on performing a vaginal delivery)
Number of subjects: 113
Study: 19031073

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17824291

Group type: EXPERIMENTAL
Intervention: Eprosartan (477.5 +/- 143.7 mg/d)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Telmisartan (65.9 +/- 17.7 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Candesartan (11.9 +/- 4.0 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No sartan treatment (Control group)
Number of subjects: 80
Study: 15232456

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (two-dose regime)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Autologous donation
Number of subjects: 40
Study: 11686355

Group type: EXPERIMENTAL
Intervention: Once-daily low molecular weight heparin
Number of subjects: 1522

Group type: COMPARATOR
Intervention: Twice-daily low molecular weight heparin
Number of subjects: 1522
Study: 9645829

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5-25.0 mg/d) with the addition of atenolol (25-50 mg/d) or reserpine (0.05-0.10 mg/d) if needed
Number of subjects: 4336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4336

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5-25.0 mg/d)
Number of subjects: 4336
Study: 8142860

Group type: EXPERIMENTAL
Intervention: Propranolol + Nifedipine
Number of subjects: 11
Study: 3434628

Group type: EXPERIMENTAL
Intervention: Negatively ionized atmosphere
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ambient atmosphere (Control)
Number of subjects: 28
Study: 29606292

Group type: EXPERIMENTAL
Intervention: Femtosecond reverse side-cut CCIs (Group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Femtosecond forward side-cut CCIs (Group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Manual CCIs (Group C)
Number of subjects: 45
Study: 27996321

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Self-Monitored Blood Glucose (SMBG)
Number of subjects: 448
Study: 24919887

Group type: EXPERIMENTAL
Intervention: 75 μg of desogestrel/die for 5 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: 100 mg of danazol/die for 5 weeks
Number of subjects: 200
Study: 22929389

Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 1401

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1401
Study: 15998708

Group type: EXPERIMENTAL
Intervention: Powdered North American ginseng (3 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12023684

Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 9895091

Group type: EXPERIMENTAL
Intervention: Fiberoptic-guided airway exchange of the esophageal-tracheal Combitube (ETC)
Number of subjects: 40
Study: 7735418

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (0.15 mg/kg per dose)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (normal saline aerosol)
Number of subjects: 33
Study: 1675029

Group type: EXPERIMENTAL
Intervention: 100 micrograms of purified gonococcal pilus vaccine given intradermally on day 1 and day 14
Number of subjects: 3123

Group type: COMPARATOR
Intervention: Placebo given intradermally on day 1 and day 14
Number of subjects: 3123

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 3123
Study: 6115661

Group type: EXPERIMENTAL
Intervention: Flunitrazepam, ketamine and nitrous oxide in oxygen
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pethidine, thiopentone, nitrous oxide in oxygen and halothane
Number of subjects: 96
Study: 31240591

Group type: EXPERIMENTAL
Intervention: DEPART technique using indocyanine green and methylene blue for identification of arm sentinel nodes
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Control group (standard axillary lymph node dissection without DEPART)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: DEPART technique
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1191
Study: 29258064

Group type: EXPERIMENTAL
Intervention: Hall Technique (HT)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Non-restorative caries treatment (NRCT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Conventional restorations (CR)
Number of subjects: 169
Study: 25218067

Group type: EXPERIMENTAL
Intervention: Attention control training
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Approach-bias re-training (varieties)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Sham-training control condition
Number of subjects: 615
Study: 23748419

Group type: EXPERIMENTAL
Intervention: BIA
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Skinfolds
Number of subjects: 97

Group type: COMPARATOR
Intervention: DXA
Number of subjects: 97
Study: 21457202

Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg subcutaneously at baseline followed by 40 mg every other week for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (identical-looking injections with no active ingredient)
Number of subjects: 21
Study: 18621051

Group type: EXPERIMENTAL
Intervention: Infected with Plasmodium falciparum
Number of subjects: 1523

Group type: EXPERIMENTAL
Intervention: Heavy Schistosoma mansoni infection
Number of subjects: 1523

Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 1523

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 1523

Group type: COMPARATOR
Intervention: Uninfected children
Number of subjects: 1523
Study: 16843806

Group type: EXPERIMENTAL
Intervention: Nonabsorbable suture anchor (G II, DePuy Mitek)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Absorbable suture anchor (Panalok, DePuy Mitek)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Both interventions (nonabsorbable and absorbable anchors)
Number of subjects: 124
Study: 12969091

Group type: EXPERIMENTAL
Intervention: High-dose therapy (rabeprazole 20 mg b.d., amoxicillin 1 g b.d. for 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 500 mg b.d., and tinidazole 500 mg b.d. for 5 days)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Low-dose therapy (rabeprazole 20 mg b.d., amoxicillin 1 g b.d. for 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 250 mg b.d., and tinidazole 500 mg b.d. for 5 days)
Number of subjects: 152
Study: 11025888

Group type: EXPERIMENTAL
Intervention: VDD pacing
Number of subjects: 10

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 10
Study: 9131949

Group type: EXPERIMENTAL
Intervention: Picumeterol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GR 63411B
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8406151

Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (25 micrograms subcutaneously three times daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Omeprazole (40 mg once a day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined therapy of SMS 201‐995 and omeprazole
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3530612

Group type: EXPERIMENTAL
Intervention: Insulin infusion at 20 m‐units min‐1 m‐2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Insulin infusion at 80 m‐units min‐1 m‐2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Insulin infusion at 200 m‐units min‐1 m‐2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Insulin infusion at all three rates
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Insulin infusion at all three doses
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 5
Study: 29859968

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4256

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 4256
Study: 27173100

Group type: EXPERIMENTAL
Intervention: Tecarfarin
Number of subjects: 607

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Tecarfarin (CYP2C9 interacting drugs)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Warfarin (CYP2C9 interacting drugs)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Tecarfarin (mechanical heart valves)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Warfarin (mechanical heart valves)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Tecarfarin (CYP2C9 variant allele)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Warfarin (CYP2C9 variant allele)
Number of subjects: 607
Study: 24997182

Group type: EXPERIMENTAL
Intervention: pegaptanib 0.3 mg
Number of subjects: 221

Group type: COMPARATOR
Intervention: sham injections
Number of subjects: 221
Study: 22727623

Group type: EXPERIMENTAL
Intervention: Web-based educational program providing individual audit data for sensitivity, specificity, recall rate, positive predictive value, and cancer detection rate; duration not specified.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Web-based educational program (same as above)
Number of subjects: 31
Study: 20042528

Group type: EXPERIMENTAL
Intervention: Price discounts (12.5%) on healthier foods
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Tailored nutrition education
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Discounts plus education
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1104
Study: 18723335

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 1776
Study: 15753241

Group type: EXPERIMENTAL
Intervention: 0.25 mg lorazepam
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1.0 mg lorazepam
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12767566

Group type: EXPERIMENTAL
Intervention: Lycopene (2 mg twice daily)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 10877197

Group type: EXPERIMENTAL
Intervention: STARCH
Number of subjects: 20
Study: 8892714

Group type: EXPERIMENTAL
Intervention: 0.2 mg of NA and 1 microg of EE2
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: 0.5 mg of NA and 2.5 microg of EE2
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: 1 mg of NA and 5 microg of EE2
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: 1 mg of NA and 10 microg of EE2
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: 1 microg of EE2
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: 2.5 microg of EE2
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: 5 microg of EE2
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: 10 microg of EE2
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: NA-EE2 treatments
Number of subjects: 1265

Group type: COMPARATOR
Intervention: EE2
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1265
Study: 1676825

Group type: EXPERIMENTAL
Intervention: British group (unrestricted prescribing of H2-receptor antagonists)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Australian group (H2-receptor antagonists allowed only after gastroscopy or barium meal)
Number of subjects: 139
Study: 6888838

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 0
Study: 31268641

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard informing process (Control)
Number of subjects: 115
Study: 28125365

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study: 26094224

Group type: EXPERIMENTAL
Intervention: Home arm (SMS reminder + postal home collection kit)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Clinic arm (SMS alone)
Number of subjects: 600
Study: 25975103

Group type: EXPERIMENTAL
Intervention: Rengalin
Number of subjects: 146
Study: 21636735

Group type: EXPERIMENTAL
Intervention: Exercise + Supplement (E + S) with 70 g of honey
Number of subjects: 39

Group type: COMPARATOR
Intervention: Exercise (E) with 70 g of artificial sweetener
Number of subjects: 39
Study: 18068829

Group type: EXPERIMENTAL
Intervention: folkloric dance‐based exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: control
Number of subjects: 40
Study: 17331388

Group type: EXPERIMENTAL
Intervention: Tulobuterol tape
Number of subjects: 233

Group type: COMPARATOR
Intervention: Tulobuterol tablet
Number of subjects: 233
Study: 15385136

Group type: EXPERIMENTAL
Intervention: Sartorius transposition
Number of subjects: 61

Group type: COMPARATOR
Intervention: No sartorius transposition (Control)
Number of subjects: 61
Study: 11605106

Group type: EXPERIMENTAL
Intervention: Telesurgical approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional laparoscopic approach
Number of subjects: 0
Study: 10511435

Group type: EXPERIMENTAL
Intervention: Attention directed to luminance stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention directed to chromatic stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of attended and unattended conditions
Number of subjects: 0
Study: 7625475

Group type: EXPERIMENTAL
Intervention: D-cycloserine 50 mg/day
Number of subjects: 9
Study: 2620671

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg p.o. (n = 21)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg i.v. over 30 min (n = 15)
Number of subjects: 36
Study: 1255322

Group type: EXPERIMENTAL
Intervention: 1 gm/kg of salt‐poor human serum albumin intravenously one hour before exchange transfusions
Number of subjects: 42

Group type: COMPARATOR
Intervention: Simple exchanges
Number of subjects: 42